Multicenter, open label single arm study in which 140 subjects with CRI who are currently
receiving SC darbepoetin alfa once every other week will receive darbepoetin alfa once every
4 weeks for 24 weeks. Upon enrollment into this study, subjects will receive darbepoetin alfa
once every 4 weeks for 24 weeks. The initial dose will be equivalent to the subject's total
dose in the month preceding enrollment. Doses may be titrated to maintain the Hb
concentration in the target range.